Business
Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA55
Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA55\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, TX, Oct. 10, 2017\n\n\n\nStudy Shows Successful Delivery in Brain Cancer Patients and Reassuring Safety Profile\n\n\n\nTORONTO and HOUSTON, TX, Oct. 10, 2017 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX \"MDNA\"), a clinical stage immuno-oncology company, announced that new clinical data presented today at the 2017 Congress of Neurological Surgeons (\"CNS\") (Boston, MA), demonstrated successful delivery in brain cancer patients and a reassuring safety profile for MDNA55, the company's lead immunotherapeutic agent targeting the interleukin-4 receptor (IL-4R).\n\nIn the study MDNA55-05, investigators administer MDNA55 directly into Glioblastoma (\"GBM\") brain tumors using a technique known as Convection Enhanced Delivery (\"CED\"). CED allows precision delivery of MDNA55 at high concentrations into the tumor tissue while avoiding exposure to the rest of the body. The current Phase 2b clinical trial plans to enroll 52 adult patients with recurrent GBM (\"rGBM\") at leading brain cancer centers in the US. A planned review of the first treated patients was conducted to ensure patient safety and to assess effectiveness of the CED technique.\n\nSenior investigator John H. Sampson MD, PhD, of Duke University Medical Center Department of Neurosurgery, who presented the data at the CNS meeting stated, \"Our initial analyses show a substantially higher proportion of the target tissue being covered than in previous similar trials. In some cases, close to 100% of the tumor and the 1cm margin around it (at risk for tumor spread) has been successfully covered.\"\n\n\"Drug delivery to the brain has been a challenge and these initial data are a significant advance in our attempt to safely and efficiently deliver our targeted cancer immunotherapy agent MDNA55,\" said Martin Bexon MD, Head of Clinical Development for ...